The researchers found inferior outcomes and higher accrued costs associated with alloimmunization in patients with myelodysplastic syndromes (MDS), a disease that relies on transfusion of red blood ...

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS. Receiving early red blood cell transfusion for low-risk ...

Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical hematopoietic stem cell transplantation (haplo-HSCT), according to a study ...

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study ...

The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research. Associations ...